Cross-species tropism and antigenic landscapes of circulating SARS-CoV-2 variants.

Yali Zhang1,2 Min Wei1,2 Yangtao Wu1,2 Juan Wang1,2 Yuting Hong1,2 Yang Huang1,2 Lunzhi Yuan1,2 Jian Ma1,2 Kai Wang1,2 Shaojuan Wang1,2 Yang Shi1,2 Zikang Wang1,2 Huilin Guo1,2 Jin Xiao1,2 Chuanlai Yang1,2 Jianghui Ye1,2 Jijing Chen1,2 Yuxi Liu1,2 Baorong Fu1,2 Miaolin Lan1,2 Peixuan Gong1,2 Zehong Huang1,2 Yingying Su1,2 Yixin Chen1,2 Tianying Zhang1,2 Jun Zhang1,2 Huachen Zhu3,4 Hai Yu1,5 Quan Yuan1,6 Tong Cheng1,7 Yi Guan3,8 Ningshao Xia1,9,10
Affiliations 10 institutions
  1. State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, Xiamen, P.R. China
  2. National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Life Sciences, Xiamen University, Xiamen, P.R. China.
  3. State Key Laboratory of Emerging Infectious Diseases, The University of Hong Kong, Hong Kong, P.R. China
  4. Joint Institute of Virology (Shantou University and The University of Hong Kong), Guangdong-Hongkong Joint Laboratory of Emerging Infectious Diseases, Shantou University, Shantou, P.R. China.
  5. National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Life Sciences, Xiamen University, Xiamen, P.R. China. Electronic address: [email protected].
  6. National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Life Sciences, Xiamen University, Xiamen, P.R. China. Electronic address: [email protected].
  7. National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Life Sciences, Xiamen University, Xiamen, P.R. China. Electronic address: [email protected].
  8. Joint Institute of Virology (Shantou University and The University of Hong Kong), Guangdong-Hongkong Joint Laboratory of Emerging Infectious Diseases, Shantou University, Shantou, P.R. China. Electronic address: [email protected].
  9. National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Life Sciences, Xiamen University, Xiamen, P.R. China
  10. Research Unit of Frontier Technology of Structural Vaccinology, Chinese Academy of Medical Sciences, Xiamen University, Xiamen, P.R. China. Electronic address: [email protected].

Abstract

Mutations in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike receptor-binding domain (RBD) may alter viral host tropism and affect the activities of neutralizing antibodies. Here, we investigated 153 RBD mutants and 11 globally circulating variants of concern (VOCs) and variants of interest (VOIs) (including Omicron) for their antigenic changes and cross-species tropism in cells expressing 18 ACE2 orthologs. Several RBD mutations strengthened viral infectivity in cells expressing ACE2 orthologs of non-human animals, particularly those less susceptible to the ancestral strain. The mutations surrounding amino acids (aas) 439-448 and aa 484 are more likely to cause neutralization resistance. Strikingly, enhanced cross-species infection potential in the mouse and ferret, instead of the neutralization-escape scores of the mutations, account for the positive correlation with the cumulative prevalence of mutations in humans. These findings present insights for potential drivers of circulating SARS-CoV-2 variants and provide informative parameters for tracking and forecasting spreading mutations.

Supporting text Virus Host Location
ACE2 receptor 4 CP: Immunology 1 CP: Microbiology 7 cross-species tropism 1 neutralization resistance 1 RBD mutations 1 SARS-CoV-2 variants 88 variants of concern 5 variants of interest 1 COVID-19 425 SARS-CoV-2 453 Animals 1948 Ferrets 79 Humans 1440 Membrane Glycoproteins 26 Mice 253 Spike Glycoprotein, Coronavirus 274 Tropism 11 Viral Envelope Proteins 60 SARS-CoV-2 variants 86 spike protein, SARS-CoV-2 157

Evidence records

1 total
Experimental Infection
1 records · 1 evidence types
Evidence type
1 records
OVE5776
Key finding

SARS-CoV-2 receptor-binding domain mutants and variants, including Omicron, were experimentally tested for cross-species infectivity in cells expressing 18 ACE2 orthologs, revealing enhanced susceptibility in mouse and ferret ACE2-expressing cells.

Virus
Host
Location
Not specified
Supporting text

we investigated 153 RBD mutants and 11 globally circulating variants of concern (VOCs) and variants of interest (VOIs) (including Omicron) for their antigenic changes and cross-species tropism in cells expressing 18 ACE2 orthologs

Method
cell-based infectivity assay | receptor-binding domain mutation analysis | ACE2 ortholog expression system
Experimental system
cells expressing ACE2 orthologs from multiple species in a receptor-expression infection assay